Help us KnockOut Alzheimer's
If someone you love is one of the 46 million people worldwide suffering from Alzheimer’s disease today, you have a new friend to join you in the fight! I’m Todd Ault and I’m on a mission to KnockOut Alzheimer’s in my lifetime. If you have a moment, let me show how I’ve put my money and efforts where my mouth is to fight this memory-killing opponent and how you can make a profound difference in joining the fight and finding a cure for as little as $5.
I’ve used the experience obtained through my 30-year Street Fighting career (Wall St. specifically) to invest in heavyweight contenders who have shown they can help put Alzheimer's against the ropes as we work to knock it down. The goal is to first decelerate the progression of the disease, the next goal is to decrease the number of people with Alzheimer's, and the ultimate goal is to have a treatment that delivers a KnockOut blow to Alzheimer's once and for all.
When you’ve been on Wall Street as long as me, you learn to sift through B.S. real fast. When it came to finding the promising contenders out there who are fighting Alzheimer’s, I wanted to back the fighters who show the most promise and have the best fundamentals. That means they are grounded and don’t have moonshot dreams. These are scientists and inventors that use proven therapies or compounds in new ways that large pharmaceutical companies have no interest in developing. The therapeutics we have are not some esoteric feel-good concept; this is hardcore science created by the University of South Florida, which is a shareholder in a company with which I am heavily involved and control, Alzamend Neuro, Inc. The University of South Florida ranks as one of the top 20 institutions in the nation for patented research and their portfolio of proprietary solutions.
Big Pharma has no interest in solving Alzheimer's if there’s not a giant payday involved. That means we have to go toe-to-toe against the fiercest of opponents on our own. For me, it’s personal, my family has been ravaged by Alzheimer’s and I can't bear to see anyone else having to suffer the crushing punishment from this disease, which brutalizes families every day.
If you’ve read this far, bless you. My father is suffering right now with Alzheimer’s and it’s killing me. My wife Kristy’s mother passed away from Alzheimer’s. If you’ve read this far, you most likely know someone who has suffered from the disease. I’m terribly sorry for your family if that’s the case, and I want to tell you something important; there IS hope. I have seen the research and talked to those on the frontline fighting Alzheimer’s. Over $8.2 Million has been invested to get Alzamend to the point where we believe we’re now about 6 months from entering an all-important milestone, Phase 1 human clinical trials.
I’m not some billionaire who has unlimited cash; otherwise, I would fund this all myself and give the treatments away for free to anyone who needed them. I am asking for your help, to join my fight to KnockOut Alzheimer's in our lifetime! Please contribute now! To get to the next milestone, we need to raise $5 Million. The funds will be used to help get Alzamend’s two drugs into patients in 2020 via Phase 1 human clinical trials. If we get the results anticipated, the benefits to those battling Alzheimer's will be monumental and will provide tremendous hope for many. If you want to be in this fight, if you want to be in it with me, join me now and just know I will not stop until we KnockOut Alzheimer's permanently.
Why Alzamend Neuro?
As a veteran of Wall Street veteran for the past 30+ years specializing in mergers and acquisitions and leading activist deals, I felt compelled to do something AD given the lack of progress achieved. It seems amazing that still today that most of the medical research to find a treatment or cure for Alzheimer's has been poorly funded and has so for many years. This is especially clear when you compare funding for AD against the funding achieved from private and government sources for the other 5 leading medical causes of death for the same time period. I already knew from my experience in the pharmaceutical sector that countless medical research projects at universities, colleges, private institutions, and bio-techs often are left “on the shelf” and never commercialized if not underfunded.
The good news is since Alzamend was established, the company has raised over $8.2 million in capital to fund its preclinical activities and to start the process to move both therapeutics through the FDA IND process. Alzamend has a small, but talented team that needs these funds to complete the IND application process and start the Phase 1 human clinical trials in 2020.
The Science
The two therapeutics solutions from Alzamend are:
AL001 (aka LiProSal), is a unique composition of lithium salicylate and proline that uses a new method of preparation and distribution, co-crystallization. This treatment allows for lower dosages to penetrate the blood-brain barrier and broaden lithium’s therapeutic value delivered. We believe based on the preclinical results that this treatment may greatly reduce or eliminate the symptoms of agitation and other endpoints for mild to moderate stage patients diagnosed with Alzheimer’s.
Lithium salts have a long history of human consumption beginning in the 1800’s. In psychiatry, they have been used to treat mania and as a prophylactic for depression since the mid-20th century. Today, lithium salts are used as a mood stabilizer for the treatment of bipolar disorder. Although the FDA has approved no medications as safe and effective treatments for suicidality, lithium has proven to be the only drug that consistently reduces suicidality in patients with neuropsychiatric disorders. Despite these effective medicinal uses, current FDA-approved lithium pharmaceutics (lithium carbonate and lithium citrate) are limited by a narrow therapeutic window that requires regular blood monitoring of plasma lithium levels and blood chemistry by a clinician to mitigate adverse events. This treatment offers improved physiochemical properties compared to existing forms of lithium, giving it the potential to be developed as an anti-suicidal drug or for use against mood disorders.
Recent evidence suggests that lithium may be very effective for both the treatment and prevention of Alzheimer’s. Unlike traditional medications that only address a single therapeutic target, lithium appears to be neuroprotective through several modes of action. Moreover, results from recent clinical studies suggest that lithium treatment may reduce dementia development while preserving cognitive function and reducing biomarkers associated with AD.
AL002 (aka CAO22W), an adjuvant-free therapeutic vaccine intended for use as a treatment or prophylactic for patients diagnosed with Alzheimer’s. This patented and licenses solution is a mutant-peptide immunotherapy and is intended to work by stimulating the body’s own immune system to prevent the formation and breakdown of beta amyloids, which build up in the brain to form a “plaque,” and subsequently block the neurological brain signals, ultimately leading to the symptoms and onset of Alzheimer’s.
We believe that strategies to strengthen the immune system in the elderly, who are most susceptible to the development of Alzheimer’s, could greatly enhance the effectiveness of immune-based approaches towards Alzheimer’s. Alzamend’s novel immune-based methodology attempts to inhibit the natural process of immunological aging by restoring the balance of the immune system through immunomodulation.
How Can You Join the Fight?
Use the hashtag #KOALZ
Share the GoFundMe campaign with your friends. Please always include the keyword, #KOALZ. Join me to KnockOut Alzheimer’s in my lifetime. It may be too late for my family, but now I’m fighting for yours.
For more information on Ault Life Sciences go to https://aultlifesciences.com; for Information about Alzamend Neuro go to https://Alzamend.com; for the audited filings and important disclosures about Alzamend Neuro, Inc please got to https://www.sec.gov/Archives/edgar/data/1677077/000121465919005495/s827191k.htm
Sincerely,
Todd